Treatment of Critically Ill COVID-19 Patients with Vilobelimab, a First-in-Class Anti-C5a Antibody

Time: 2:00 pm
day: Track B - Day 1 PM


  • C5a/C5aR axis plays an essential role in COVID-19 pathogenesis
  • C5a-indued neutrophil activation is a driving force in the development of severe COVID-19
  • Understand how Vilobelimab treatment improves survival in critically ill COVID-19 patients